The groundbreaking rise of Sildenafil presented a considerable prospect for shareholders , but its period has ended, creating a complex landscape. Generic versions have entered the market , cutting into revenues and putting pressure on profit margins . While leading healthcare companies maintain a stake in this field , the potential remains clouded